ANI Pharmaceuticals (NasdaqGM:ANIP) FY Conference Transcript

ANI Pharmaceuticals FY Conference Summary Company Overview - ANI Pharmaceuticals is a profitable high-growth biopharmaceutical organization focusing on rare diseases, projecting over $1 billion in sales for 2026 with significant growth expected [2][22] - The company reported a 44% year-over-year growth in 2025, with a projected growth of 23% for 2026 [2][22] Core Business Segments Rare Disease Business - The rare disease segment is expected to represent about 60% of total company revenues in 2026, with projected sales of $618 million to $658 million, reflecting a 51% growth from 2025 [2][9] - Cortrophin Gel, the lead asset, is anticipated to grow 55% to 65%, reaching $540 million to $575 million in 2026 [8][22] - The rare disease business has shown an 84% growth in 2025, driven by key specialties including neurology, rheumatology, nephrology, and pulmonology [4][9] Generics Business - The Generics segment achieved a 28% year-over-year growth in 2025, supported by strong R&D capabilities and operational execution [5][18] - The company plans to maintain a cadence of 10 to 15 new product launches annually and invests a high single-digit percentage of Generics revenue into R&D [6][19] Strategic Priorities for 2026 1. Accelerate Transformation into Rare Disease Company: Focus on maximizing growth opportunities for Cortrophin Gel and expanding into under-penetrated specialty indications [5][12] 2. Continue Execution on Generics Business: Leverage operational excellence and R&D capabilities to enhance cash generation [6][19] 3. Disciplined Capital Allocation: Explore opportunities for inorganic growth in the rare disease sector while investing in Generics R&D [6][21] Market Dynamics - The ACTH market, which includes Cortrophin, is projected to approach $1 billion in sales by 2025, with a 45% year-over-year growth [10] - The company has identified significant unmet needs in various indications, with a focus on severe acute gouty arthritis flares, representing an addressable population of approximately 285,000 patients [11][12] Financial Performance - ANI Pharmaceuticals reported $883 million in revenues for 2025, with adjusted non-GAAP EBITDA of $230 million, reflecting a 47% year-over-year growth [4][22] - The company enters 2026 with over $286 million in cash and a net leverage of 1.5 times debt, indicating strong financial health [21][22] Conclusion - ANI Pharmaceuticals is well-positioned for long-term growth, leveraging cash flows from its Generics business to fuel investments in its rare disease segment, aiming to transform into a leading rare disease company [20][22]